All In Biotech

Drug Trial Radar · NCT06300203

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit (IL-4Rα) in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment: A Randomized, Double-Blind, Placebo-controlled IIT Study

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 18, 2024

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Beijing Tongren HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • Interleukin-4 receptor respondersBiological

    Interleukin-4 receptor was injected subcutaneously.

  • PlaceboOther

    Placebo was injected subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average change from baseline in daily retrospective total nasal symptom score (rTNSS) at week 2.Time frame: up to Week 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.